By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on AbbVie's acquisition of Apogee, with concerns about execution risk, competition, and near-term dilution outweighing the potential long-term benefits for some, while others see it as a strategic defensive move to protect AbbVie's immunology franchise.
Risk: Execution risk, competition from Dupixent-like therapies, and the chance Apogee's pipeline never delivers a durable, scalable product.
Opportunity: Zumilokibart's extended dosing interval potentially creating a 'sticky' patient base and protecting AbbVie's long-term terminal value in the atopic dermatitis market.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
AbbVie (NYSE:ABBV) was one of the livelier stocks in Monday’s trading session. It was also one of the better-performing equities, gaining more than 6% that day. Much of this was due to a splashy new acquisition that will strengthen its already considerable presence in a lucrative segment of the pharmaceutical market.
Before market open, AbbVie and Apogee Therapeutics (NASDAQ:APGE) announced they had signed a definitive agreement for AbbVie to acquire its peer.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
The deal, valued at roughly $10.9 billion, obligates AbbVie to pay Apogee stockholders $135.11 per share in cash. The two companies did not hesitate to mention that their boards of directors have both unanimously approved the transaction.
It is still subject to the approval of Apogee shareholders. That, however, appears inevitable, as the agreed purchase price is nearly 47% above the stock’s closing price on the previous trading day. The transaction will also have to be cleared by the relevant regulatory authorities.
AbbVie and Apogee said they expect it to close in the third quarter of this year.
Apogee is a clinical-stage biotech with several promising investigational programs — hence the premium that AbbVie was willing to pay to acquire it.
The company has developed two monotherapies and combined them with secondary mechanisms to create a pair of combination drugs. All target the proteins that power chronic immune and inflammatory disorders.
Its leading drug program (and the most advanced in the pipeline) is zumilokibart, a monoclonal antibody currently in Phase 2 testing for moderate-to-severe atopic dermatitis (a.k.a. eczema), and in Phase 1b for asthma. It has done extremely well in its trials for eczema.
What’s arguably most promising about zumilokibart is that its effects are relatively long-lasting; patients would only need to take it once every three to six months, compared to once every two weeks for treatments currently on the market. So if it’s ultimately approved, it should be very competitive.
Another plus for the drug is its potential versatility, as it’s also being developed for asthma and eosinophilic esophagitis (allergic inflammation of the esophagus).
The company’s APG279, meanwhile, is a similarly versatile drug currently being developed for the treatment of eczema. If successfully brought to market, it would compete with the highly successful Dupixent marketed by Sanofi and Regeneron Pharmaceuticals.
Finally, there’s the monotherapy APG333, which is combined with zumilokibart in another investigational drug, APG273. Both currently target asthma and COPD.
In the joint press release, AbbVie and Apogee said their deal is expected to be accretive to the former’s earnings per share (EPS) not in accordance with generally accepted accounting principles (GAAP) starting in 2032.
Given that Apogee hasn’t yet entered Phase 3 trials for zumilokibart, that’s a fairly quick turnaround for a clinical-stage asset.
I feel this acquisition is one of the better and more promising ones for AbbVie, given the obvious strength and potential of Apogee’s pipeline. AbbVie continues to grow in clever ways, both through its proprietary development efforts and through biotech acquisitions.
That said, Apogee isn’t coming cheap; The Wall Street Journal cited a Citigroup analysis stating that in purchasing it, AbbVie will take a $0.14-per-share hit to its non-GAAP (adjusted) EPS this year, and $0.46 per share in 2027.
Still, the consensus analyst estimates for the two years stand at $14.24 and $16.25, respectively, so I don’t think the stock will suffer. I also believe AbbVie’s dividend, currently yielding more than 3%, won’t come under pressure.
All in all, then, I think the Apogee deal boosts the buy case for AbbVie’s already-attractive stock
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,305! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,293,148!
Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 22, 2026. *
Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The deal could unlock long-run EPS growth, but near-term dilution and execution risk make the upside contingent on zumilokibart's success amid competitive dynamics."
AbbVie’s $10.9B cash bid for Apogee signals conviction that zumilokibart and APG assets could meaningfully augment its immunology franchise. The 135.11 per-share cash offer and a ~47% premium imply strong confidence in late-stage potential and an eventual EPS kicker many years out (2032 accretion). Yet near-term costs loom: Citi cites a non-GAAP EPS hit of about $0.14 this year and $0.46 in 2027, with debt-financing likely, which could pressure margins and financial flexibility before any upside materializes. The real fragility is execution risk—competition from Dupixent-like therapies, payer dynamics, and the chance Apogee’s pipeline never delivers a durable, scalable product.
Strongest counter: Apogee’s flagship asset is still Phase 2 and the premium rests on a long-shot, delayed payoff; if zumilokibart falters or rivals gain share, near-term dilution and higher debt costs could erase the expected upside.
"The acquisition of Apogee is primarily a defensive strategy to secure a differentiated, long-acting asset that protects AbbVie's dominant market share in immunology from future competitive erosion."
AbbVie’s $10.9 billion acquisition of Apogee is a defensive masterstroke, not just a growth play. With Humira’s patent cliff in the rearview, the market is hyper-focused on AbbVie’s ability to defend its immunology fortress against the likes of Skyrizi and Rinvoq. Zumilokibart’s extended dosing interval (every 3-6 months) is the real value driver here, potentially creating a 'sticky' patient base that makes it harder for biosimilars or newer entrants to switch patients away. While the $0.46 EPS dilution by 2027 is non-trivial, AbbVie’s massive free cash flow supports this R&D bridge. They are effectively buying a moat to protect their long-term terminal value in the $20B+ atopic dermatitis market.
The acquisition is a high-stakes gamble on a Phase 2 asset; if zumilokibart hits any safety signals in Phase 3 or fails to show superior efficacy over established blockbusters like Dupixent, AbbVie will have incinerated over $10 billion in shareholder capital.
"ABBV is paying a 47% premium for clinical-stage assets with binary Phase 2/3 risk and no EPS contribution until 2032, making this a bet on execution in a crowded immunology space, not a defensive dividend play."
The article frames this as a slam-dunk: AbbVie buying a clinical-stage biotech with a promising pipeline at a 47% premium. But the math is deceptive. Zumilokibart is Phase 2 for eczema, Phase 1b for asthma — clinical-stage means binary risk. The article buries that EPS accretion doesn't arrive until 2032, and there's a $0.46/share drag in 2027. At $14.24 and $16.25 consensus EPS those years, that's material. The real question: is ABBV paying $10.9B for a 2032 payoff in a market where immunology competition (Dupixent, others) is brutal? The dividend safety claim needs scrutiny.
If zumilokibart's dosing advantage (once every 3-6 months vs. every 2 weeks) translates to real market share capture in a $20B+ eczema market, the 2032 accretion timeline could compress and the premium evaporates. Clinical risk is real, but so is optionality upside.
"Near-term EPS dilution and pre-Phase 3 execution risk outweigh the headline pipeline addition for AbbVie over the next three years."
AbbVie's $10.9B all-cash purchase of Apogee at a 47% premium adds zumilokibart, a Phase 2 asset with quarterly-to-biannual dosing that could compete in atopic dermatitis and asthma. Yet the deal delivers non-GAAP EPS dilution of $0.14 this year and $0.46 in 2027 before turning accretive only in 2032, while Apogee's programs still face Phase 3, regulatory, and reimbursement risks in a market already dominated by Dupixent and Skyrizi. The 3%+ dividend appears safe on consensus estimates, but execution slippage or competitive pressure could extend the payback period well beyond current projections.
If zumilokibart's durability data hold in Phase 3 and capture even modest share from twice-weekly injectables, the 2032 accretion timeline could compress materially and justify the premium faster than the $0.46 hit implies.
"Near-term financing and execution risk could erode the premium's value even if the Phase 2 asset ultimately delivers."
Claude correctly flags binary risk, but the bigger lever is capital structure. Even if zumilokibart delivers, AbbVie's all-cash $10.9B at 47% premium leaves debt-service and potential rating pressure if rates stay higher than modeled. If Apogee slips in Phase 3 or payer dynamics sour pricing, the near-term dilution (non-GAAP EPS hits through 2027) could persist longer than 2032. That's a non-trivial downside not fully priced in.
"The acquisition is less about long-term EPS accretion and more about securing a defensive moat that prevents future market share erosion in the immunology segment."
Claude and ChatGPT are fixated on the 2032 accretion timeline, but they are ignoring the strategic 'defensive' value Gemini mentioned. AbbVie isn't just buying a drug; they are buying a patent-protected barrier to entry. If zumilokibart’s dosing interval forces a change in the standard of care, the entire market shifts. The $10.9B isn't just a R&D bet; it’s an insurance policy against their own Skyrizi and Rinvoq eventually facing the same pricing pressures Humira endured.
"Dosing convenience ≠ market displacement; Dupixent's incumbency is a higher hurdle than patent protection alone."
Gemini's 'defensive moat' framing deserves scrutiny. Patent protection on dosing interval alone doesn't stop biosimilar competition—it delays it. More critical: Dupixent already owns the eczema market with proven efficacy and payer relationships. AbbVie's $10.9B assumes zumilokibart can *displace* entrenched standard-of-care, not just coexist. That's a market-share cannibalization bet, not a moat. If it merely adds incremental share, the 2032 accretion evaporates and the all-cash structure becomes indefensible.
"Dosing interval creates no moat without displacing Dupixent, so the all-cash deal risks extending dilution beyond 2027."
Gemini overstates the defensive moat by treating quarterly dosing as an automatic barrier. That interval only matters if Phase 3 proves superior efficacy or safety versus Dupixent; otherwise payers will keep patients on the incumbent, leaving AbbVie with an incremental asset and the full $0.46 2027 EPS drag plus debt-service costs. The all-cash structure then converts an option into a sunk cost rather than insurance for Skyrizi and Rinvoq.
The panel is divided on AbbVie's acquisition of Apogee, with concerns about execution risk, competition, and near-term dilution outweighing the potential long-term benefits for some, while others see it as a strategic defensive move to protect AbbVie's immunology franchise.
Zumilokibart's extended dosing interval potentially creating a 'sticky' patient base and protecting AbbVie's long-term terminal value in the atopic dermatitis market.
Execution risk, competition from Dupixent-like therapies, and the chance Apogee's pipeline never delivers a durable, scalable product.